Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Sapanisertib (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 24 Apr 2017 Status changed from not yet recruiting to recruiting.
- 20 Mar 2017 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.
- 20 Mar 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.